Novocaine0.4%

Novocaine is an ester-type topical (surface) local anesthetic used in ophthalmology. It is indicated for producing rapid, short-duration anesthesia of the cornea and conjunctiva for diagnostic and minor surgical eye procedures.

Established/Approved Uses

• Tonometry (measurement of intraocular pressure)
• Gonioscopy
• Removal of corneal or conjunctival foreign bodies
• Removal of corneal sutures
• Conjunctival and corneal scraping for diagnostic sampling
• Fitting of diagnostic (rigid) contact lenses
• Minor ophthalmic surgical procedures (e.g., pterygium excision, punctal plug insertion) where brief surface anesthesia is sufficient

Adjunct Use

Novocaine is commonly combined with a diagnostic dye (fluorescein sodium) as a pre-instillation anesthetic to allow comfortable applanation tonometry and corneal/conjunctival staining examinations.

Novocaine is intended for short, single or occasional procedural use by a healthcare professional and is not intended for continued self-administration by patients.

Each mL of ophthalmic solution typically contains Oxybuprocaine Hydrochloride 4 mg (0.4% w/v) as the active ingredient, along with preservatives (e.g., benzalkonium chloride, where applicable) and other pharmaceutical excipients to maintain isotonicity and stability. Preservative-free single-dose (minims) presentations are also available for single-use application.

Novocaine (also known as benoxinate hydrochloride) is a synthetic ester-type local anesthetic used exclusively as a topical ophthalmic preparation. It produces rapid-onset (within 15-20 seconds), short-duration surface anesthesia of the eye, making it useful for brief diagnostic and minor procedural interventions. Unlike some other topical ophthalmic anesthetics, it is generally well tolerated with minimal initial stinging.

Novocaine is supplied as a sterile ophthalmic solution for instillation into the conjunctival sac and is not intended for injection or systemic administration.

Novocaine belongs to the therapeutic class of topical ophthalmic local anesthetics (ester-type), used specifically for ocular surface anesthesia.

Mechanism of action: Oxybuprocaine Hydrochloride is an ester-linked local anesthetic that reversibly blocks nerve impulse generation and conduction by decreasing the permeability of the sensory nerve membrane to sodium ions. This stabilizes the neuronal membrane and inhibits the depolarization required for impulse propagation, producing localized loss of sensation in the cornea and conjunctiva.

Onset and duration: Anesthetic effect begins within about 15-20 seconds of instillation and typically lasts approximately 10-20 minutes, which is sufficient for most short diagnostic or minor procedural purposes.

Absorption: Systemic absorption following topical ophthalmic use is minimal under normal conditions, though absorption may be increased with corneal epithelial damage or repeated dosing.

• For topical ophthalmic use only - instill directly into the lower conjunctival sac.
• Avoid touching the dropper tip to the eye, eyelid, or any surface to prevent contamination.
• If using single-dose (minims) units, discard the container after a single use; do not reuse on another patient or at another time.
• Excess solution may be blotted from the eyelid with a clean tissue.
• Novocaine must be administered by, or under the direct supervision of, a qualified healthcare professional.

Clinically significant drug interactions with Novocaine are limited given its topical ophthalmic use and minimal systemic absorption. The following should be noted:

• Other ophthalmic preparations: When multiple topical eye medications are required, space administration apart (typically several minutes) to prevent one drop from washing out another and to avoid additive local irritation.
• Preservative interactions: Products containing benzalkonium chloride may interact with soft contact lenses (absorption/discoloration); contact lenses should be removed before use.

No clinically significant systemic drug interactions have been well established for Novocaine at recommended topical ophthalmic doses.

Most adverse effects of Novocaine are local and transient.

• Transient stinging or burning sensation immediately after instillation (usually mild)
• Transient conjunctival redness or hyperemia
• Punctate corneal epithelial changes (superficial punctate keratitis), particularly with repeated or prolonged use
• Blurred vision (transient)
• Rarely, hypersensitivity/allergic reactions (lid edema, itching, contact dermatitis)
• Rarely, with repeated or excessive use: corneal edema, epithelial erosion, or delayed corneal healing (see Precautions and Warnings)

There are limited controlled data on the use of Novocaine in human pregnancy. Systemic absorption after topical ophthalmic instillation is expected to be minimal, but as with any medication, Novocaine should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. A physician should be consulted before use in pregnant patients.

It is not known whether topically applied Novocaine is excreted in human milk. Caution is advised, and a physician should be consulted before use in breastfeeding mothers.

• Not for prolonged or repeated self-administration: Novocaine is intended only for short-term, professionally supervised diagnostic or procedural use. Repeated or prolonged use by patients can delay corneal epithelial healing and carries a risk of corneal toxicity, persistent epithelial defects, or corneal ulceration, sometimes with permanent visual impairment.
• Protect the anesthetized eye: Because the corneal (blink/protective) reflex is temporarily suppressed, the treated eye should be protected from rubbing, foreign bodies, and accidental trauma until normal sensation returns (usually within 10-20 minutes).
• Masking of injury: Novocaine can mask the pain of a serious eye injury or infection; do not rely on symptom relief as a sign of resolution of an underlying problem.
• Not for injection or systemic use: Novocaine is formulated for topical ophthalmic use only and must never be injected or swallowed.
• Contact lenses: Remove contact lenses before instillation; avoid reinserting until normal corneal sensation has fully returned.
• Single-patient use: To reduce the risk of cross-contamination, use single-dose (minims) preparations for one patient only, and discard multi-dose bottles that may have contacted the eye or eyelashes.

Overdose is unlikely with correct topical ophthalmic use of Novocaine, given the small instilled volumes. Accidental ingestion, injection, or excessive/prolonged ocular application could theoretically lead to systemic local anesthetic toxicity, with symptoms such as dizziness, tremor, drowsiness, blurred vision, or, in severe cases, seizures or cardiac/respiratory depression.

If overdose, accidental ingestion, or a severe/unexpected reaction is suspected, seek immediate medical attention or contact a poison control center/emergency services. Do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed when not in use. Discard single-dose (minims) units after one use. Keep out of reach of children.

Pediatric Use

Novocaine is used in children for ophthalmic examinations and minor procedures under the direct supervision of an eye care professional; however, formal safety and efficacy data in neonates and very young infants are limited, and use in this age group requires particular caution.

Elderly

No specific dose adjustment is required for elderly patients; Novocaine is commonly used in this population for routine tonometry and cataract-related procedures.

Renal/Hepatic Impairment

No specific dose adjustment is established or generally required for topical ophthalmic use of Novocaine, as systemic exposure is minimal.

Novocaine is intended for single or occasional short-term procedural use only, immediately before a diagnostic or minor surgical eye procedure. It is not intended for continued, repeated, or long-term use by patients.

Ester-type topical ophthalmic local anesthetic.

Oxybuprocaine Hydrochloride blocks both the initiation and conduction of nerve impulses in sensory nerve endings of the cornea and conjunctiva by decreasing membrane permeability to sodium ions, thereby stabilizing the neuronal membrane and preventing depolarization, resulting in reversible, localized loss of sensation.

Novocaine is used in the pediatric population for ophthalmic diagnostic examinations (e.g., tonometry) and minor procedures (e.g., foreign body removal), but only under the direct supervision of a qualified eye care professional. Formal safety and efficacy data specifically in neonates and infants are limited, and the labeling position for very young children is generally that safety and efficacy have not been fully established; use in this group should be individualized and carefully supervised.